Literature DB >> 12731678

Pseudoprolongation of the prothrombin time during treatment with recombinant factor VIIa for bleeding in a patient with a spontaneous factor VIII inhibitor.

Marcus E Carr, Jan G Kuhn, Erika J Martin, Ann R Tidwell, Maura K Hagan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12731678     DOI： 10.1007/bf02983792

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  7 in total

1.  Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects.

Authors:  P W Friederich; M Levi; K A Bauer; G P Vlasuk; W E Rote; D Breederveld; T Keller; M Spataro; S Barzegar; H R Büller
Journal:  Circulation       Date:  2001-05-29       Impact factor: 29.690

2.  Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures.

Authors:  H A Cooper; C P Jones; E Campion; H R Roberts; U Hedner
Journal:  Haemophilia       Date:  2001-09       Impact factor: 4.287

3.  Pseudo-prolongation of the partial thromboplastin time.

Authors:  L G Smith; C S Kitchens
Journal:  Am J Clin Pathol       Date:  1983-11       Impact factor: 2.493

4.  Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors.

Authors:  A Shirahata; T Kamiya; J Takamatsu; T Kojima; K Fukutake; M Arai; H Hanabusa; H Tagami; A Yoshioka; G M Shima; G H Naka; G S Fujita; Y Minamoto; J Kamizono; H Saito
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

5.  Delayed, reduced or inhibited thrombin production reduces platelet contractile force and results in weaker clot formation.

Authors:  M E Carr; E J Martin; S L Carr
Journal:  Blood Coagul Fibrinolysis       Date:  2002-04       Impact factor: 1.276

6.  The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study.

Authors:  C R Hay; C Negrier; C A Ludlam
Journal:  Thromb Haemost       Date:  1997-12       Impact factor: 5.249

7.  Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study.

Authors:  B G Macik; C M Lindley; J Lusher; W T Sawyer; A L Bloom; J F Harrison; K Baird-Cox; K Birch; S Glazer; H R Roberts
Journal:  Blood Coagul Fibrinolysis       Date:  1993-08       Impact factor: 1.276
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.